Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

Biopharmaceutical Factors Influencing Drug Product Design: Overview

Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...
Drug Product Performance: In Vitro–In Vivo Correlation01:20

Drug Product Performance: In Vitro–In Vivo Correlation

In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while adhering...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
Inflammatory Bowel Disease IV: Clinical Manifestations01:20

Inflammatory Bowel Disease IV: Clinical Manifestations

Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The disease course is marked...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gene editing in allergic diseases: Identification of novel pathways and impact of deleting allergen genes.

The Journal of allergy and clinical immunology·2024
Same author

Author Correction: JT002, a small molecule inhibitor of the NLRP3 inflammasome for the treatment of autoinflammatory disorders.

Scientific reports·2023
Same author

JT002, a small molecule inhibitor of the NLRP3 inflammasome for the treatment of autoinflammatory disorders.

Scientific reports·2023
Same author

Molecular networks in atopic mothers impact the risk of infant atopy.

Allergy·2022
Same author

Autophagy-associated immune dysregulation and hyperplasia in a patient with compound heterozygous mutations in <i>ATG9A</i>.

Autophagy·2022
Same author

Registries are shaping how we think about primary immunodeficiency diseases.

The Journal of allergy and clinical immunology·2022

Related Experiment Video

Updated: Jul 21, 2026

A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection
09:12

A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection

Published on: June 15, 2018

Differences between IGIV products: impact on clinical outcome.

Erwin W Gelfand1

  • 1Division of Cell Biology, Department of Pediatrics, National Jewish Medical and Research Center, Denver, Colorado, USA. gelfande@njc.org

International Immunopharmacology
|March 1, 2006
PubMed
Summary

Choosing the right immune globulin intravenous (IGIV) product is crucial due to manufacturing and formulation differences. This review examines variations in IGIV products to guide clinical decisions for better patient outcomes.

Related Experiment Videos

Last Updated: Jul 21, 2026

A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection
09:12

A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection

Published on: June 15, 2018

Area of Science:

  • Immunology
  • Pharmacology
  • Biotechnology

Background:

  • Intravenous immune globulin (IGIV) use has surged for immunodeficiency and autoimmune diseases.
  • Expansion brings challenges in product selection and emerging concerns.
  • Product availability fluctuates, necessitating informed choices.

Purpose of the Study:

  • To review differences among available US IGIV products.
  • To assess how variations in manufacturing, viral reduction, and formulation impact clinical outcomes.
  • To guide optimal IGIV product selection for individual patients.

Main Methods:

  • Comparative review of currently available IGIV products in the United States.
  • Analysis of manufacturing processes, virus inactivation methods, and final product compositions.
  • Examination of potential effects on safety and efficacy.

Main Results:

  • Significant variability exists in IGIV product manufacturing and formulation.
  • Differences in product characteristics may influence clinical safety and efficacy.
  • No single IGIV product is universally superior; selection is patient-dependent.

Conclusions:

  • Understanding IGIV product variability is essential for effective patient management.
  • Informed product selection can optimize therapeutic benefits and minimize risks.
  • Further research may clarify specific outcome differences between IGIV products.